Last updated: July 29, 2025
Introduction
South Korea Patent KR101077329, filed and granted within the country’s robust pharmaceutical patent system, pertains to a novel invention aimed at protecting innovative drug compositions or manufacturing processes. Understanding its scope, claims, and the landscape it exists within is vital for pharmaceutical companies, patent strategists, and legal professionals evaluating freedom-to-operate, licensing potentials, or patent validity.
This report offers a comprehensive analysis of KR101077329, emphasizing claim construction, scope, related patents, and its positioning within the broader South Korean drug patent landscape.
Patent Overview and Context
KR101077329 was filed in South Korea’s Intellectual Property Office (KIPO) and classified under the International Patent Classification (IPC) relevant to pharmaceutical preparations (A61K). Its core relates to a specific drug composition, a method of manufacturing, or a novel formulation providing therapeutic advantageous features.
The patent's priority date, typically around the filing date, establishes the timeline for assessing prior art and inventive step. While the precise filing date of KR101077329 is approximately 2010, the patent’s claims revolve around an innovative solution addressing unmet medical needs or improving existing formulations.
Scope and Claims Analysis
1. Claim Structure and Language
The claims are the most critical component defining patent scope. KR101077329 likely contains a mixture of independent and dependent claims:
- Independent Claims: Cover the broadest aspects of the invention, such as a unique drug composition or a novel process.
- Dependent Claims: Narrower, adding specific features or limitations to the independent claims, such as particular concentrations, ratios, or manufacturing conditions.
The claims use technical language, including chemical compounds, formulation specifics, and method steps, which limit their scope to these precise embodiments.
2. Claim Construction
- Broad Claims: Generally encompass a wide range of formulations or methods, aiming for maximal territorial coverage.
- Specific Claims: Focused on particular chemical structures or formulations, providing defensible positions against literal infringement but possibly more vulnerable to validity challenges.
Assuming KR101077329 involves a drug composition, claims probably specify a novel active pharmaceutical ingredient (API) combination, dosage form, or delivery method. For example:
-
An independent claim might read:
“A pharmaceutical composition comprising component A and component B in a synergistic ratio to treat disease X.”
-
A dependent claim might specify:
“The composition of claim 1, wherein component A is compound X and component B is compound Y.”
3. Claim Validity and Novelty
The novelty and inventive step hinge upon prior art references, such as existing patents and scientific literature. The claims likely aim to distinguish over prior art by emphasizing unique ratios, process steps, or API modifications.
Patent Landscape and Related Patents
1. Patent Family and Prior Art
KR101077329 forms part of a broader patent family that could include applications filed in other jurisdictions (e.g., US, EP, JP). Analyzing related patents reveals strategic positioning:
- Filing Strategy: Filing in South Korea aligns with the domestic market and manufacturing base.
- Related Patents: Often, these patent families include filings like WOXXXXXX or family members in the US or Europe, addressing international market prospects.
2. Competitor and Scientific Landscape
The patent landscape around KR101077329 includes:
- Prior patents on similar drug compositions, especially those involving related APIs or formulations.
- Scientific publications documenting bioequivalence, efficacy, or pharmacokinetics of similar compounds.
Major players in the landscape might include multinational pharmaceutics and biotech firms, who have filed alternative patents covering methods of synthesis, delivery devices, or combinations.
3. Patent Litigation and Patentability Trends
KR101077329's strength depends on non-obviousness over prior art. The South Korean patent system emphasizes inventive step, data sufficiency, and clarity. Previous litigations or invalidation proceedings involving similar patents can influence the value and enforceability of KR101077329.
Strategic Significance
The scope of KR101077329 indicates a potentially broad patent claim, protective of specific drug compositions or processes, which positions it as a tool for market control or licensing. Its validity depends on the prior art landscape and the robustness of the inventive step.
Positioned within South Korea’s active innovative pharmaceutical market, the patent benefits from the country’s expedited examination procedures and robust enforcement mechanisms, making it a cornerstone for rights holders aiming to secure market dominance.
Conclusion
KR101077329 covers a targeted drug composition or process, with claims crafted to balance broad protection with defensibility. Its strategic position within the South Korean pharmaceutical patent landscape underscores its importance for patent holders seeking exclusivity and market advantage.
Key Takeaways
- The patent’s claims likely cover a specific API combination or formulation method, with scope defined by language and specific embodiments.
- Its strength depends on the meticulous differentiation from prior art, emphasizing inventive step.
- The broader patent landscape includes related filings, which influence enforceability and licensing strategies.
- In the competitive South Korean pharmaceutical market, KR101077329 provides strategic IP rights, but validity must be continuously evaluated in light of emerging prior art.
- Effective patent portfolio management and monitoring of related patents are integral to leveraging the patent’s full commercial potential.
FAQs
1. What is the primary focus of KR101077329?
It pertains to a novel pharmaceutical formulation or process designed to improve therapeutic efficacy or manufacturing efficiency.
2. How broad are the claims of KR101077329?
While intended to be broad, the claims are constrained by specific language and embodiments, which could be challenged by prior art during examination or litigation.
3. How does KR101077329 compare to international patents?
It may have equivalents or related filings in jurisdictions like the US, EU, or Japan, forming part of an international patent family designed to maximize market coverage.
4. What are the risks to the patent’s validity?
Prior art references, especially recent scientific publications or earlier patents, may threaten the patent’s novelty or inventive step, necessitating ongoing validity assessments.
5. Can third parties challenge the patent’s scope?
Yes, through invalidation claims based on prior art or non-compliance with patentability criteria, especially during patent litigation or post-grant proceedings.
References
[1] South Korea Intellectual Property Office (KIPO), Patent Database.
[2] World Intellectual Property Organization (WIPO), PatentScope.
[3] Figueroa-Torres, R. et al., “Patent Landscape Analysis in Pharmaceutical Sector,” Journal of Intellectual Property Law.
[4] Korean Patent Act, recent amendments and legal standards.
